← Back to Search

Kinase Inhibitor

Treatment (erdafitinib) for Lymphoma

Phase 2
Waitlist Available
Led By Alain C Mita
Research Sponsored by National Cancer Institute (NCI)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 years
Awards & highlights

Study Summary

This trial is testing a drug called erdafitinib in patients with tumors that have extra copies of the FGFR gene. Erdafitinib is a type of medication that blocks a protein causing cancer

Who is the study for?
This trial is for patients with various cancers, like multiple myeloma and lymphoma, who have tumors with an abnormal increase in FGFR gene copies. Participants should be suitable for biopsies, CT scans, MRI scans, and biospecimen collection.Check my eligibility
What is being tested?
The study is testing Erdafitinib's effectiveness on patients whose cancer involves FGFR amplifications. It's a phase II trial where Erdafitinib is given to see if it can stop the cancer cells from multiplying by blocking the action of an abnormal protein.See study design
What are the potential side effects?
Erdafitinib may cause side effects such as mouth sores, changes in nail or skin appearance, diarrhea, dry mouth or eyes, hair loss or other reactions related to kinase inhibitors.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Objective response rate
Secondary outcome measures
Overall survival
Progression free survival

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (erdafitinib)Experimental Treatment5 Interventions
Patients receive erdafitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout study. Patients may also undergo blood sample collection and tumor biopsy throughout the trial.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Erdafitinib
2017
Completed Phase 2
~150
Magnetic Resonance Imaging
2017
Completed Phase 3
~1190
Biopsy
2014
Completed Phase 4
~850
Biospecimen Collection
2004
Completed Phase 2
~1730
Computed Tomography
2017
Completed Phase 2
~2720

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)Lead Sponsor
13,657 Previous Clinical Trials
40,933,632 Total Patients Enrolled
1,381 Trials studying Lymphoma
382,365 Patients Enrolled for Lymphoma
Alain C MitaPrincipal InvestigatorECOG-ACRIN Cancer Research Group
1 Previous Clinical Trials
35 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any hazards associated with the utilization of erdafitinib in patients?

"In this Phase 2 clinical trial, the safety assessment for erdafitinib treatment by our team at Power is rated as a 2. Initial data supports its safety profile, however, there is currently no evidence backing its efficacy."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)
2018. "Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06308822.
~1 spots leftby Jun 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top